Isturisa
osilodrostat · Recordati Rare Diseases
ORPHAN AUTHORISED IN THE EUWhat Isturisa is used for
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Isturisa
- Active substance
- osilodrostat
- Disease area
- Cushing Syndrome
- Medicine group
- Corticosteroids for systemic use
- ATC code
- H02CA02
- Marketing authorisation holder
- Recordati Rare Diseases
- Authorised in the EU since
- 2020
Official information
In the USA
Same active substance: Isturisa
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Isturisa used for?
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
What is the active substance in Isturisa?
Isturisa contains osilodrostat.
Who makes Isturisa?
The EU marketing authorisation holder is Recordati Rare Diseases.
Is Isturisa an orphan medicine?
Yes. Isturisa is designated an orphan medicine in the EU, for a rare disease (Cushing Syndrome).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU